Review



basic fibroblast growth factor  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 91
      Buy from Supplier

    Structured Review

    Novus Biologicals basic fibroblast growth factor
    Basic Fibroblast Growth Factor, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+basic+fgf/Recombinant+Mouse+FGF+basic%2FFGF2%2FbFGF+Protein/pm34338296-237-34-40
    Average 91 stars, based on 2 article reviews
    basic fibroblast growth factor - by Bioz Stars, 2026-09
    91/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: Muscle progenitor specification and myogenic differentiation are associated with changes in chromatin topology
    Article Snippet: PDGFRα+FLK1− cells were sorted using FACSAriaII (BD biosciences) and re-plated on gelatin-coated dishes using EB differentiation media supplemented with 1 μg/ml Dox and 10 ng/ml mouse basic-FGF (Preprotech). .. Cells were expanded using the same media with Dox for 4 additional days before harvesting them for analysis. iPax7 and iPax7_3xFlag muscle progenitors were grown on 0.1% gelatin-coated culture plates in GlutaMAX supplemented IMDM (Gibco) with 15% stem cell qualified fetal bovine serum (Gemini), 1% penicillin/streptomycin (Corning), 200 μg/ml bovine holo-transferrin (Sigma), 50 μg/ml l -ascorbic acid (Sigma), 4.5 mM 1-thioglycerol (Sigma), and 5 ng/ml recombinant mouse bFGF (R&D systems). .. Cells were treated with 0.75 μg/ml Dox (Sigma) for the expression of Pax7 or Pax7_3xFlag and were assessed 3 days after removing Dox from the culture media for differentiation.

    Article Title: Klotho expression in long bones regulates FGF23 production during renal failure
    Article Snippet: Total RNA was purified with the RNeasy Mini Kit (Qiagen, Germantown, MD, USA). .. Recombinant mouse bFGF was purchased from R&D Systems (Minneapolis, MN, USA). .. Recombinant human FGF23 was a gift from V. Shalhoub and W. Richards (Amgen).

    Article Title: The vitamin K-dependent anticoagulant factor, protein S, inhibits multiple VEGF-A-induced angiogenesis events in a Mer- and SHP2-dependent manner.
    Article Snippet: .. Recombinant mouse bFGF was from R&D Systems. .. Recombinant human bFGF and recombinant VEGF-A 165 isoform, both mouse and human, were from Invitrogen.

    Article Title: Isolation of adult pituitary stem/progenitor cell clusters located in the parenchyma of the rat anterior lobe.
    Article Snippet: Briefly, 16-well chamber slides (0.4 cm2/well) (Thermo Fisher Scientific) were coated with undiluted Matrigel (25 μl/cm2), followed by seeding 1–5 dense cell clusters suspended in 1:50 diluted Matrigel in DMEM/F-12 without serum. .. To test the effects of growth factors, dense cell clusters were cultured by the overlay 3D culture method and 2D culture (described below) including 20 ng/ml each of recombinant mouse bFGF (R&D, Minneapolis, MN, USA) and recombinant human EGF (R&D) in DMEM/F-12 without serum. .. To assess the proliferative activity of dense cell clusters, bromodeoxyuridine (BrdU) (10 μM; Roche Diagnostics GmbH, Mannheim, Germany) was added to the culture medium at the time of cell seeding.

    Article Title: Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential.
    Article Snippet: Objectives We studied whether plasma levels of angiogenic factors VEGF and placental growth factor (PlGF) in coronary artery disease patients or undergoing cardiac surgery are modified, and whether those factors modulate endothelial progenitor’s angiogenic potential.. Methods and results A total of 143 patients’ plasmas from two different studies were analyzed (30 coronary artery disease patients, 30 patients with stable angina, coupled with 30 age and sex-matched controls; 53 patients underwent cardiac surgery).. Among factors screened, only PlGF was found significantly increased in these pathological populations.

    Article Title: Angiogenesis Inhibition by a Short 13 Amino Acid Peptide Sequence of Tetrastatin, the α4(IV) NC1 Domain of Collagen IV
    Article Snippet: .. Four hundred μL of Matrigel mix composed of growth factor-reduced Matrigel (Dutscher, Brumath, France) supplemented with 100 ng/mL recombinant mouse VEGF (R&D System-Bio-Techne, Lille, France), 350 ng/mL of recombinant mouse bFGF (R&D System-Bio-Techne, Lille, France) and 25 UI/mL of Heparin (R&D System-Bio-Techne, Lille, France) were injected into the left flank of each mouse. ..

    Cell Culture:

    Article Title: The canonical smooth muscle cell marker TAGLN is present in endothelial cells and is involved in angiogenesis.
    Article Snippet: .. HUVECs (Cellworks, Buckingham, UK) were cultured on gelatincoated plates in Dulbecco’s modified Eagle’s medium/F12 (DMEM/F12; Nacalai Tesque, Inc., Kyoto Japan) supplemented with 10% fetal bovine serum (FBS, PAA Laboratories, Linz, Austria) and 10 ng/ml basic fibroblast growth factor (b-FGF; NBP2-35152; Novus Biologicals, CO, USA). .. HUVECs were passaged by dissociation using 0.05% trypsin (T3924; Sigma-Aldrich, St Louis, MO, USA) and were used until passage seven.

    Article Title: Isolation of adult pituitary stem/progenitor cell clusters located in the parenchyma of the rat anterior lobe.
    Article Snippet: Briefly, 16-well chamber slides (0.4 cm2/well) (Thermo Fisher Scientific) were coated with undiluted Matrigel (25 μl/cm2), followed by seeding 1–5 dense cell clusters suspended in 1:50 diluted Matrigel in DMEM/F-12 without serum. .. To test the effects of growth factors, dense cell clusters were cultured by the overlay 3D culture method and 2D culture (described below) including 20 ng/ml each of recombinant mouse bFGF (R&D, Minneapolis, MN, USA) and recombinant human EGF (R&D) in DMEM/F-12 without serum. .. To assess the proliferative activity of dense cell clusters, bromodeoxyuridine (BrdU) (10 μM; Roche Diagnostics GmbH, Mannheim, Germany) was added to the culture medium at the time of cell seeding.

    Modification:

    Article Title: The canonical smooth muscle cell marker TAGLN is present in endothelial cells and is involved in angiogenesis.
    Article Snippet: .. HUVECs (Cellworks, Buckingham, UK) were cultured on gelatincoated plates in Dulbecco’s modified Eagle’s medium/F12 (DMEM/F12; Nacalai Tesque, Inc., Kyoto Japan) supplemented with 10% fetal bovine serum (FBS, PAA Laboratories, Linz, Austria) and 10 ng/ml basic fibroblast growth factor (b-FGF; NBP2-35152; Novus Biologicals, CO, USA). .. HUVECs were passaged by dissociation using 0.05% trypsin (T3924; Sigma-Aldrich, St Louis, MO, USA) and were used until passage seven.

    In Vivo:

    Article Title: Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential.
    Article Snippet: Objectives We studied whether plasma levels of angiogenic factors VEGF and placental growth factor (PlGF) in coronary artery disease patients or undergoing cardiac surgery are modified, and whether those factors modulate endothelial progenitor’s angiogenic potential.. Methods and results A total of 143 patients’ plasmas from two different studies were analyzed (30 coronary artery disease patients, 30 patients with stable angina, coupled with 30 age and sex-matched controls; 53 patients underwent cardiac surgery).. Among factors screened, only PlGF was found significantly increased in these pathological populations.

    Matrigel Assay:

    Article Title: Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential.
    Article Snippet: Objectives We studied whether plasma levels of angiogenic factors VEGF and placental growth factor (PlGF) in coronary artery disease patients or undergoing cardiac surgery are modified, and whether those factors modulate endothelial progenitor’s angiogenic potential.. Methods and results A total of 143 patients’ plasmas from two different studies were analyzed (30 coronary artery disease patients, 30 patients with stable angina, coupled with 30 age and sex-matched controls; 53 patients underwent cardiac surgery).. Among factors screened, only PlGF was found significantly increased in these pathological populations.

    Injection:

    Article Title: Angiogenesis Inhibition by a Short 13 Amino Acid Peptide Sequence of Tetrastatin, the α4(IV) NC1 Domain of Collagen IV
    Article Snippet: .. Four hundred μL of Matrigel mix composed of growth factor-reduced Matrigel (Dutscher, Brumath, France) supplemented with 100 ng/mL recombinant mouse VEGF (R&D System-Bio-Techne, Lille, France), 350 ng/mL of recombinant mouse bFGF (R&D System-Bio-Techne, Lille, France) and 25 UI/mL of Heparin (R&D System-Bio-Techne, Lille, France) were injected into the left flank of each mouse. ..



    Similar Products

    recombinant mouse fibroblast growth factors fgf basic protein  (R&D Systems)
    94
    R&D Systems recombinant mouse fibroblast growth factors fgf basic protein
    Recombinant Mouse Fibroblast Growth Factors Fgf Basic Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+basic+fgf/Recombinant+Mouse+FGF-10+Protein/pmc12978157-73-27-35
    Average 94 stars, based on 1 article reviews
    recombinant mouse fibroblast growth factors fgf basic protein - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    recombinant mouse fgf basic protein  (R&D Systems)
    94
    R&D Systems recombinant mouse fgf basic protein
    Recombinant Mouse Fgf Basic Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+basic+fgf/Recombinant+Mouse+FGF-10+Protein/pmc12978157-171-28-33
    Average 94 stars, based on 1 article reviews
    recombinant mouse fgf basic protein - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    recombinant mouse fgf2 protein  (R&D Systems)
    95
    R&D Systems recombinant mouse fgf2 protein
    Morphology of FGF-treated calvarial suture explants. A, Schematic outlining the experimental procedure. B, Phase contrast images of a representative calvarial suture (COR suture) explant after 8 days in culture with recombinant <t>FGF2</t> protein (100 ng/mL) revealing the presence of a tube-like structure (red arrows) sprouting from the edge (green arrow) of the suture (magnification at 10×). C, 20× magnification of the red dashed boxed area in panel B. Panel D highlights the presence of round cells; bottom panel D(i) is a magnification at 40× of the boxed area in panel D, and green arrows mark the small, round, and bright cells. E, Phase contrast image of FGF2 treated PF suture shows a morphology similar to FGF2 treated COR suture. Green arrows point to the suture edge. Red arrows mark tube-like structures and blue arrow a lacunae-like formation. COR calvarial suture explant control. Green arrows point the suture edge. Magnification at 20×. F, Phase contrast image of untreated COR calvarial suture explant control. G, Phase contrast image of untreated PF calvarial suture explant control. Green arrows point the suture edge. H, Cartoon depicting the following experimental steps. I-K, Representative phase contrast images of cells isolated by FACS sorting from FGF2 treated COR suture explants cultured in presence of FGF2 (100 ng/mL), followed by VEGF (150 ng/mL) addition at day 4 for additional 48 hours (total 6 days of culture). I, Cells display a foci formation (dashed green circle) and sprouting of tubular structures in panels J and K, (green arrows). Magnification at 20× and 40×. L, Control cells isolated from untreated calvarial suture explants grow in a monolayer without forming structures resembling either foci or tube-like structures (magnification at 20×). Experiments were performed at least 3 times. Scale bars: 100 µm in panel B; 50 µm panels (C, D, E, F, G, I, J, I, L); 20 µm in panel D(i) and K. Abbreviations: COR, coronal; FGF, fibroblast growth factor.
    Recombinant Mouse Fgf2 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+basic+fgf/Recombinant+Mouse+FGF+basic%2FFGF2%2FbFGF+Protein/pmc12932999-38-0-5
    Average 95 stars, based on 1 article reviews
    recombinant mouse fgf2 protein - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    fb 500 mouse lif polygene transgenics  (R&D Systems)
    96
    R&D Systems fb 500 mouse lif polygene transgenics
    Morphology of FGF-treated calvarial suture explants. A, Schematic outlining the experimental procedure. B, Phase contrast images of a representative calvarial suture (COR suture) explant after 8 days in culture with recombinant <t>FGF2</t> protein (100 ng/mL) revealing the presence of a tube-like structure (red arrows) sprouting from the edge (green arrow) of the suture (magnification at 10×). C, 20× magnification of the red dashed boxed area in panel B. Panel D highlights the presence of round cells; bottom panel D(i) is a magnification at 40× of the boxed area in panel D, and green arrows mark the small, round, and bright cells. E, Phase contrast image of FGF2 treated PF suture shows a morphology similar to FGF2 treated COR suture. Green arrows point to the suture edge. Red arrows mark tube-like structures and blue arrow a lacunae-like formation. COR calvarial suture explant control. Green arrows point the suture edge. Magnification at 20×. F, Phase contrast image of untreated COR calvarial suture explant control. G, Phase contrast image of untreated PF calvarial suture explant control. Green arrows point the suture edge. H, Cartoon depicting the following experimental steps. I-K, Representative phase contrast images of cells isolated by FACS sorting from FGF2 treated COR suture explants cultured in presence of FGF2 (100 ng/mL), followed by VEGF (150 ng/mL) addition at day 4 for additional 48 hours (total 6 days of culture). I, Cells display a foci formation (dashed green circle) and sprouting of tubular structures in panels J and K, (green arrows). Magnification at 20× and 40×. L, Control cells isolated from untreated calvarial suture explants grow in a monolayer without forming structures resembling either foci or tube-like structures (magnification at 20×). Experiments were performed at least 3 times. Scale bars: 100 µm in panel B; 50 µm panels (C, D, E, F, G, I, J, I, L); 20 µm in panel D(i) and K. Abbreviations: COR, coronal; FGF, fibroblast growth factor.
    Fb 500 Mouse Lif Polygene Transgenics, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+basic+fgf/Recombinant+Human+FGF+basic%2FFGF2%2FbFGF+(146+aa)+Protein/pm41605217-255-169-166
    Average 96 stars, based on 1 article reviews
    fb 500 mouse lif polygene transgenics - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    bfgf  (R&D Systems)
    95
    R&D Systems bfgf
    Morphology of FGF-treated calvarial suture explants. A, Schematic outlining the experimental procedure. B, Phase contrast images of a representative calvarial suture (COR suture) explant after 8 days in culture with recombinant <t>FGF2</t> protein (100 ng/mL) revealing the presence of a tube-like structure (red arrows) sprouting from the edge (green arrow) of the suture (magnification at 10×). C, 20× magnification of the red dashed boxed area in panel B. Panel D highlights the presence of round cells; bottom panel D(i) is a magnification at 40× of the boxed area in panel D, and green arrows mark the small, round, and bright cells. E, Phase contrast image of FGF2 treated PF suture shows a morphology similar to FGF2 treated COR suture. Green arrows point to the suture edge. Red arrows mark tube-like structures and blue arrow a lacunae-like formation. COR calvarial suture explant control. Green arrows point the suture edge. Magnification at 20×. F, Phase contrast image of untreated COR calvarial suture explant control. G, Phase contrast image of untreated PF calvarial suture explant control. Green arrows point the suture edge. H, Cartoon depicting the following experimental steps. I-K, Representative phase contrast images of cells isolated by FACS sorting from FGF2 treated COR suture explants cultured in presence of FGF2 (100 ng/mL), followed by VEGF (150 ng/mL) addition at day 4 for additional 48 hours (total 6 days of culture). I, Cells display a foci formation (dashed green circle) and sprouting of tubular structures in panels J and K, (green arrows). Magnification at 20× and 40×. L, Control cells isolated from untreated calvarial suture explants grow in a monolayer without forming structures resembling either foci or tube-like structures (magnification at 20×). Experiments were performed at least 3 times. Scale bars: 100 µm in panel B; 50 µm panels (C, D, E, F, G, I, J, I, L); 20 µm in panel D(i) and K. Abbreviations: COR, coronal; FGF, fibroblast growth factor.
    Bfgf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+basic+fgf/Recombinant+Mouse+FGF+basic%2FFGF2%2FbFGF+Protein/bio_rxiv__64898__2025__12__22__695902-228-41-43
    Average 95 stars, based on 1 article reviews
    bfgf - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    fgf  (R&D Systems)
    95
    R&D Systems fgf
    Morphology of FGF-treated calvarial suture explants. A, Schematic outlining the experimental procedure. B, Phase contrast images of a representative calvarial suture (COR suture) explant after 8 days in culture with recombinant <t>FGF2</t> protein (100 ng/mL) revealing the presence of a tube-like structure (red arrows) sprouting from the edge (green arrow) of the suture (magnification at 10×). C, 20× magnification of the red dashed boxed area in panel B. Panel D highlights the presence of round cells; bottom panel D(i) is a magnification at 40× of the boxed area in panel D, and green arrows mark the small, round, and bright cells. E, Phase contrast image of FGF2 treated PF suture shows a morphology similar to FGF2 treated COR suture. Green arrows point to the suture edge. Red arrows mark tube-like structures and blue arrow a lacunae-like formation. COR calvarial suture explant control. Green arrows point the suture edge. Magnification at 20×. F, Phase contrast image of untreated COR calvarial suture explant control. G, Phase contrast image of untreated PF calvarial suture explant control. Green arrows point the suture edge. H, Cartoon depicting the following experimental steps. I-K, Representative phase contrast images of cells isolated by FACS sorting from FGF2 treated COR suture explants cultured in presence of FGF2 (100 ng/mL), followed by VEGF (150 ng/mL) addition at day 4 for additional 48 hours (total 6 days of culture). I, Cells display a foci formation (dashed green circle) and sprouting of tubular structures in panels J and K, (green arrows). Magnification at 20× and 40×. L, Control cells isolated from untreated calvarial suture explants grow in a monolayer without forming structures resembling either foci or tube-like structures (magnification at 20×). Experiments were performed at least 3 times. Scale bars: 100 µm in panel B; 50 µm panels (C, D, E, F, G, I, J, I, L); 20 µm in panel D(i) and K. Abbreviations: COR, coronal; FGF, fibroblast growth factor.
    Fgf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+basic+fgf/Recombinant+Mouse+FGF+basic%2FFGF2%2FbFGF+Protein/pmc12832107-272-22-23
    Average 95 stars, based on 1 article reviews
    fgf - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Morphology of FGF-treated calvarial suture explants. A, Schematic outlining the experimental procedure. B, Phase contrast images of a representative calvarial suture (COR suture) explant after 8 days in culture with recombinant FGF2 protein (100 ng/mL) revealing the presence of a tube-like structure (red arrows) sprouting from the edge (green arrow) of the suture (magnification at 10×). C, 20× magnification of the red dashed boxed area in panel B. Panel D highlights the presence of round cells; bottom panel D(i) is a magnification at 40× of the boxed area in panel D, and green arrows mark the small, round, and bright cells. E, Phase contrast image of FGF2 treated PF suture shows a morphology similar to FGF2 treated COR suture. Green arrows point to the suture edge. Red arrows mark tube-like structures and blue arrow a lacunae-like formation. COR calvarial suture explant control. Green arrows point the suture edge. Magnification at 20×. F, Phase contrast image of untreated COR calvarial suture explant control. G, Phase contrast image of untreated PF calvarial suture explant control. Green arrows point the suture edge. H, Cartoon depicting the following experimental steps. I-K, Representative phase contrast images of cells isolated by FACS sorting from FGF2 treated COR suture explants cultured in presence of FGF2 (100 ng/mL), followed by VEGF (150 ng/mL) addition at day 4 for additional 48 hours (total 6 days of culture). I, Cells display a foci formation (dashed green circle) and sprouting of tubular structures in panels J and K, (green arrows). Magnification at 20× and 40×. L, Control cells isolated from untreated calvarial suture explants grow in a monolayer without forming structures resembling either foci or tube-like structures (magnification at 20×). Experiments were performed at least 3 times. Scale bars: 100 µm in panel B; 50 µm panels (C, D, E, F, G, I, J, I, L); 20 µm in panel D(i) and K. Abbreviations: COR, coronal; FGF, fibroblast growth factor.

    Journal: Stem Cells Translational Medicine

    Article Title: FGF2 alters the calvarial suture niche homeostasis shifting skeletal stem cell/progenitors toward an osteo-angiogenic coupling fate

    doi: 10.1093/stcltm/szag003

    Figure Lengend Snippet: Morphology of FGF-treated calvarial suture explants. A, Schematic outlining the experimental procedure. B, Phase contrast images of a representative calvarial suture (COR suture) explant after 8 days in culture with recombinant FGF2 protein (100 ng/mL) revealing the presence of a tube-like structure (red arrows) sprouting from the edge (green arrow) of the suture (magnification at 10×). C, 20× magnification of the red dashed boxed area in panel B. Panel D highlights the presence of round cells; bottom panel D(i) is a magnification at 40× of the boxed area in panel D, and green arrows mark the small, round, and bright cells. E, Phase contrast image of FGF2 treated PF suture shows a morphology similar to FGF2 treated COR suture. Green arrows point to the suture edge. Red arrows mark tube-like structures and blue arrow a lacunae-like formation. COR calvarial suture explant control. Green arrows point the suture edge. Magnification at 20×. F, Phase contrast image of untreated COR calvarial suture explant control. G, Phase contrast image of untreated PF calvarial suture explant control. Green arrows point the suture edge. H, Cartoon depicting the following experimental steps. I-K, Representative phase contrast images of cells isolated by FACS sorting from FGF2 treated COR suture explants cultured in presence of FGF2 (100 ng/mL), followed by VEGF (150 ng/mL) addition at day 4 for additional 48 hours (total 6 days of culture). I, Cells display a foci formation (dashed green circle) and sprouting of tubular structures in panels J and K, (green arrows). Magnification at 20× and 40×. L, Control cells isolated from untreated calvarial suture explants grow in a monolayer without forming structures resembling either foci or tube-like structures (magnification at 20×). Experiments were performed at least 3 times. Scale bars: 100 µm in panel B; 50 µm panels (C, D, E, F, G, I, J, I, L); 20 µm in panel D(i) and K. Abbreviations: COR, coronal; FGF, fibroblast growth factor.

    Article Snippet: Recombinant mouse FGF2 protein (#3139, R&D System) was added at concentration of 100 ng/mL.

    Techniques: Recombinant, Control, Isolation, Cell Culture

    Bulk RNA-Seq profiling of skeletal stem cell/progenitor population isolated from FGF2 treated and untreated sutures. A and B, Heatmaps of endothelial cell and endothelial progenitor cell marker genes, highlight a distinct upregulation of endothelial and endothelial progenitor cells (EPC) in FGF2 treated cells. Red color: upregulation (≥3-fold); Green color: downregulation. (−≥3-fold). The (+) symbol points to genes that are upregulated in the cell populations analyzed. C, Heatmap of osteogenic marker downregulation in cells as above. D, Validation of up- and down-regulation of key endothelial and osteogenic markers by RT-PCR analysis. E, Diagram/cartoon summarizing the trend in the expression profiles of key endothelial and osteogenic markers up- or downregulated by (≥3-fold) in cells isolated from FGF2 treat and untreated sutures.

    Journal: Stem Cells Translational Medicine

    Article Title: FGF2 alters the calvarial suture niche homeostasis shifting skeletal stem cell/progenitors toward an osteo-angiogenic coupling fate

    doi: 10.1093/stcltm/szag003

    Figure Lengend Snippet: Bulk RNA-Seq profiling of skeletal stem cell/progenitor population isolated from FGF2 treated and untreated sutures. A and B, Heatmaps of endothelial cell and endothelial progenitor cell marker genes, highlight a distinct upregulation of endothelial and endothelial progenitor cells (EPC) in FGF2 treated cells. Red color: upregulation (≥3-fold); Green color: downregulation. (−≥3-fold). The (+) symbol points to genes that are upregulated in the cell populations analyzed. C, Heatmap of osteogenic marker downregulation in cells as above. D, Validation of up- and down-regulation of key endothelial and osteogenic markers by RT-PCR analysis. E, Diagram/cartoon summarizing the trend in the expression profiles of key endothelial and osteogenic markers up- or downregulated by (≥3-fold) in cells isolated from FGF2 treat and untreated sutures.

    Article Snippet: Recombinant mouse FGF2 protein (#3139, R&D System) was added at concentration of 100 ng/mL.

    Techniques: RNA Sequencing, Isolation, Marker, Biomarker Discovery, Reverse Transcription Polymerase Chain Reaction, Expressing

    Chromatin accessibility between skeletal stem cells/progenitors derived from FGF2 treated and untreated calvarial sutures. A, Representation of enriched chromatin active motifs identified in skeletal stem cell/progenitor population isolated from FGF2 treated calvarial suture explants and predicted to function as activated transcription sites. Associated transcription factors and target genes are listed. B, Heatmap of peaks differentially expressed in cell isolated from FGF2 treated suture explants and untreated suture explants. C, Pie charts showing the proportion of chromatin open regions. D, Go-enrichment of biological processes in cells isolated from FGF2 treated suture explants unveiling blood vessel morphogenesis as major enriched process. E, KEGG enrichment analysis also reveals processes associated to angiogenesis, such as hemostasis, developmental biology, and extracellular matrix remodeling. F, Reactome enrichment analysis showing the gene ratio/intensity related to the biological processes listed in E.

    Journal: Stem Cells Translational Medicine

    Article Title: FGF2 alters the calvarial suture niche homeostasis shifting skeletal stem cell/progenitors toward an osteo-angiogenic coupling fate

    doi: 10.1093/stcltm/szag003

    Figure Lengend Snippet: Chromatin accessibility between skeletal stem cells/progenitors derived from FGF2 treated and untreated calvarial sutures. A, Representation of enriched chromatin active motifs identified in skeletal stem cell/progenitor population isolated from FGF2 treated calvarial suture explants and predicted to function as activated transcription sites. Associated transcription factors and target genes are listed. B, Heatmap of peaks differentially expressed in cell isolated from FGF2 treated suture explants and untreated suture explants. C, Pie charts showing the proportion of chromatin open regions. D, Go-enrichment of biological processes in cells isolated from FGF2 treated suture explants unveiling blood vessel morphogenesis as major enriched process. E, KEGG enrichment analysis also reveals processes associated to angiogenesis, such as hemostasis, developmental biology, and extracellular matrix remodeling. F, Reactome enrichment analysis showing the gene ratio/intensity related to the biological processes listed in E.

    Article Snippet: Recombinant mouse FGF2 protein (#3139, R&D System) was added at concentration of 100 ng/mL.

    Techniques: Derivative Assay, Isolation

    CITE sequencing analysis of skeletal stem cell/progenitor population isolated from FGF2 treated and untreated calvarial sutures. A, UMAP analysis showing changes in the representation between cells isolated from untreated (control) and FGF2 treated calvarial suture explants. B, Pies illustrating cluster-ratio overview of cell subpopulations isolated from untreated (control) and FGF2 treated suture explants (yellow lines mark clusters increased in cell representation; purple lines clusters with decreased cell representation) C, CITE-Seq Heatmap of the surface markers CD31 (PECAM-1), CD133 (Prominin-1), Sca-1 and CD200 reveals their increased levels in cells derived from FGF2 treated sutures (yellow indicates downregulation; purple upregulation). D, Violin plots showing the distribution of cells expressing the four CITE-Seq markers (top panel) and histogram of gene module scores expression (bottom panel) in control and FGF2 treated populations. E, Violin plots showing the distribution of cells expressing the four CITE-Seq markers (upper panel) in all 10 clusters and histogram of genes module scores (bottom panel). F, CITE-Seq heatmap of the surface markers CD31 (PECAM-1), CD133 (Prominin-1), Sca-1 and CD200 in all 10 clusters. G, Illustration of RNA clusters of cells expressing key markers of the osteogenic lineage by Violin plots (left panel), osteogenic modules (middle panel), and heatmap (right panel). H, Illustration of RNA clusters of cells expressing key markers of the endothelial/angiogenic lineage by Violin plots (left panels), angiogenic modules (top right panel), and heatmap (bottom right panel). I, Cartoon illustrates inferred trajectories/directions of lineages differentiation. J, Shows the velo latent time of differentiation for the different clusters. Yellow color indicates the more differentiated status of the cell populations.

    Journal: Stem Cells Translational Medicine

    Article Title: FGF2 alters the calvarial suture niche homeostasis shifting skeletal stem cell/progenitors toward an osteo-angiogenic coupling fate

    doi: 10.1093/stcltm/szag003

    Figure Lengend Snippet: CITE sequencing analysis of skeletal stem cell/progenitor population isolated from FGF2 treated and untreated calvarial sutures. A, UMAP analysis showing changes in the representation between cells isolated from untreated (control) and FGF2 treated calvarial suture explants. B, Pies illustrating cluster-ratio overview of cell subpopulations isolated from untreated (control) and FGF2 treated suture explants (yellow lines mark clusters increased in cell representation; purple lines clusters with decreased cell representation) C, CITE-Seq Heatmap of the surface markers CD31 (PECAM-1), CD133 (Prominin-1), Sca-1 and CD200 reveals their increased levels in cells derived from FGF2 treated sutures (yellow indicates downregulation; purple upregulation). D, Violin plots showing the distribution of cells expressing the four CITE-Seq markers (top panel) and histogram of gene module scores expression (bottom panel) in control and FGF2 treated populations. E, Violin plots showing the distribution of cells expressing the four CITE-Seq markers (upper panel) in all 10 clusters and histogram of genes module scores (bottom panel). F, CITE-Seq heatmap of the surface markers CD31 (PECAM-1), CD133 (Prominin-1), Sca-1 and CD200 in all 10 clusters. G, Illustration of RNA clusters of cells expressing key markers of the osteogenic lineage by Violin plots (left panel), osteogenic modules (middle panel), and heatmap (right panel). H, Illustration of RNA clusters of cells expressing key markers of the endothelial/angiogenic lineage by Violin plots (left panels), angiogenic modules (top right panel), and heatmap (bottom right panel). I, Cartoon illustrates inferred trajectories/directions of lineages differentiation. J, Shows the velo latent time of differentiation for the different clusters. Yellow color indicates the more differentiated status of the cell populations.

    Article Snippet: Recombinant mouse FGF2 protein (#3139, R&D System) was added at concentration of 100 ng/mL.

    Techniques: Sequencing, Isolation, Control, Derivative Assay, Expressing

    Skeletal stem cell/progenitor population isolated from FGF2 treated suture explants display an endothelial functional profile. A, Confocal microphotographs of an in vitro Matrigel assay performed on a pool of cells isolated from FGF2 treated PF and COR sutures and untreated sutures. Tube-like structures are observed after 18 hours. Staining dye (green color) shows the endothelial tube formation (left panel). Middle panel showing absence of tube-like structure formation in cells isolated from untreated calvarial sutures explants. Addition of the inhibitor vinblastine suppresses tube-like formation (right panel) in cells isolated from FGF2 treated suture explants. Experiments were performed three times. B, Quantification of in vitro tube-like formation by length measurement using ImageJ2 program. Results are presented as mean ± SD of tube-length formation. Analysis was performed on four independent assays. A significant difference in tube-formation length is observed in FGF2 treated cells. C, Acetylated LDL uptake by pool of cells isolated from FGF2 treated PF and COR sutures is confirmed by staining of DiI dye (left panel), whereas cells isolated from untreated calvarial suture explants do not uptake Acetylated LDL (middle panel). Likewise, in the presence of the inhibitor Protein-S (P-S), cells isolated from FGF2 treated sutures do not uptake acetylated LDL (right panel). D, Quantification of acetylated LDL uptake using ImageJ2 program (ImageJ 2, NIH) confirms a significant increased uptake by FGF2 treated cells as compared to untreated and P-S treated cells. Densitometric results are mean ± SD of the threshold levels from two independent experiments. E, H&E staining of OCT cryo-tissue sections from in vivo Matrigel plug assay showing the ability of cells isolated from FGF2 treated sutures to form vessels (left panel) which stained positive for CD31/PECAM-1 (green color) as assessed by immunofluorescence using specific antibodies (middle panel). Immunostaining using Sca-1 antibodies (red color), a marker associated with endothelial progenitor cells (EPC), reveals the presence of positive cells (right panel), and their partial colocalization with CD31/PECAM-1 positive cells as shown in panel F. G, Matrigel plug assay performed with cells isolated from untreated calvarial sutures does not reveal any vessel formation. Scale bars: 100 µm in panels A and C; 50 µm in panels E and G; 20 µm in panel F.

    Journal: Stem Cells Translational Medicine

    Article Title: FGF2 alters the calvarial suture niche homeostasis shifting skeletal stem cell/progenitors toward an osteo-angiogenic coupling fate

    doi: 10.1093/stcltm/szag003

    Figure Lengend Snippet: Skeletal stem cell/progenitor population isolated from FGF2 treated suture explants display an endothelial functional profile. A, Confocal microphotographs of an in vitro Matrigel assay performed on a pool of cells isolated from FGF2 treated PF and COR sutures and untreated sutures. Tube-like structures are observed after 18 hours. Staining dye (green color) shows the endothelial tube formation (left panel). Middle panel showing absence of tube-like structure formation in cells isolated from untreated calvarial sutures explants. Addition of the inhibitor vinblastine suppresses tube-like formation (right panel) in cells isolated from FGF2 treated suture explants. Experiments were performed three times. B, Quantification of in vitro tube-like formation by length measurement using ImageJ2 program. Results are presented as mean ± SD of tube-length formation. Analysis was performed on four independent assays. A significant difference in tube-formation length is observed in FGF2 treated cells. C, Acetylated LDL uptake by pool of cells isolated from FGF2 treated PF and COR sutures is confirmed by staining of DiI dye (left panel), whereas cells isolated from untreated calvarial suture explants do not uptake Acetylated LDL (middle panel). Likewise, in the presence of the inhibitor Protein-S (P-S), cells isolated from FGF2 treated sutures do not uptake acetylated LDL (right panel). D, Quantification of acetylated LDL uptake using ImageJ2 program (ImageJ 2, NIH) confirms a significant increased uptake by FGF2 treated cells as compared to untreated and P-S treated cells. Densitometric results are mean ± SD of the threshold levels from two independent experiments. E, H&E staining of OCT cryo-tissue sections from in vivo Matrigel plug assay showing the ability of cells isolated from FGF2 treated sutures to form vessels (left panel) which stained positive for CD31/PECAM-1 (green color) as assessed by immunofluorescence using specific antibodies (middle panel). Immunostaining using Sca-1 antibodies (red color), a marker associated with endothelial progenitor cells (EPC), reveals the presence of positive cells (right panel), and their partial colocalization with CD31/PECAM-1 positive cells as shown in panel F. G, Matrigel plug assay performed with cells isolated from untreated calvarial sutures does not reveal any vessel formation. Scale bars: 100 µm in panels A and C; 50 µm in panels E and G; 20 µm in panel F.

    Article Snippet: Recombinant mouse FGF2 protein (#3139, R&D System) was added at concentration of 100 ng/mL.

    Techniques: Isolation, Functional Assay, In Vitro, Matrigel Assay, Staining, In Vivo, Immunofluorescence, Immunostaining, Marker

    Osteo-induction assay of skeletal stem cell/progenitor population isolated from FGF2 treated and untreated suture explants. A and B, Contrast-phase microphotographs of an osteogenic assay stained with von-Kossa procedure after 21 days in culture with osteogenic medium. Cells isolated from FGF2 treated suture explants (pool of PF and COR sutures) form a very dense and patchy mineralized areas as revealed by von Kossa staining (magnification at 20×). Right panels are a magnification at 40× of the red dashed boxed areas in panel A and B, green arrows mark the presence of tube-like structures. C, Von Kossa staining of cells derived from untreated suture explants showing a diffuse ECM mineralization and some bone nodules (yellow arrows) (magnification at 20×). Right panel is a magnification at 40× of the red dashed boxed area in panel C. D, RT-PCR analysis of osteogenic and endothelial markers profiles expression of both osteogenic and angiogenic markers in cells isolated from FGF2 treated suture explants (top panel), cells express all four markers. E, Cells isolated from untreated suture explants (pool of PF and COR sutures) express less of the osteogenic marker Runx2 and low levels of Bglap and Ve-cadherin, while no expression of the endothelial marker CD3 1 ( Pecam1 ) is detected (bottom panel). Experiments were performed two times. Scale bars: 100 µm in panels A-C (left side); 50 µm in panels A-C (right side). F, Densitometric analysis of the PCR bands performed by ImageJ2 program (ImageJ 2, NIH). The densitometric results were normalized to their respective loading control ( Gapdh -bands) and presented as percent increase (100%). Results are mean ± SD of three independent analyses. Statistical significance: * P <.05.

    Journal: Stem Cells Translational Medicine

    Article Title: FGF2 alters the calvarial suture niche homeostasis shifting skeletal stem cell/progenitors toward an osteo-angiogenic coupling fate

    doi: 10.1093/stcltm/szag003

    Figure Lengend Snippet: Osteo-induction assay of skeletal stem cell/progenitor population isolated from FGF2 treated and untreated suture explants. A and B, Contrast-phase microphotographs of an osteogenic assay stained with von-Kossa procedure after 21 days in culture with osteogenic medium. Cells isolated from FGF2 treated suture explants (pool of PF and COR sutures) form a very dense and patchy mineralized areas as revealed by von Kossa staining (magnification at 20×). Right panels are a magnification at 40× of the red dashed boxed areas in panel A and B, green arrows mark the presence of tube-like structures. C, Von Kossa staining of cells derived from untreated suture explants showing a diffuse ECM mineralization and some bone nodules (yellow arrows) (magnification at 20×). Right panel is a magnification at 40× of the red dashed boxed area in panel C. D, RT-PCR analysis of osteogenic and endothelial markers profiles expression of both osteogenic and angiogenic markers in cells isolated from FGF2 treated suture explants (top panel), cells express all four markers. E, Cells isolated from untreated suture explants (pool of PF and COR sutures) express less of the osteogenic marker Runx2 and low levels of Bglap and Ve-cadherin, while no expression of the endothelial marker CD3 1 ( Pecam1 ) is detected (bottom panel). Experiments were performed two times. Scale bars: 100 µm in panels A-C (left side); 50 µm in panels A-C (right side). F, Densitometric analysis of the PCR bands performed by ImageJ2 program (ImageJ 2, NIH). The densitometric results were normalized to their respective loading control ( Gapdh -bands) and presented as percent increase (100%). Results are mean ± SD of three independent analyses. Statistical significance: * P <.05.

    Article Snippet: Recombinant mouse FGF2 protein (#3139, R&D System) was added at concentration of 100 ng/mL.

    Techniques: Isolation, Staining, Derivative Assay, Reverse Transcription Polymerase Chain Reaction, Expressing, Marker, Control